Statements (66)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Company
|
| gptkbp:acquisition |
Acquired by other companies
|
| gptkbp:approves |
FDA approvals
|
| gptkbp:awards |
Industry awards received
|
| gptkbp:business_model |
Business model overview
|
| gptkbp:ceo |
Liz Barrett
|
| gptkbp:challenges |
Market competition
|
| gptkbp:clinical_trial |
Clinical trial data
Ongoing clinical trials Clinical research initiatives Locations of clinical trials Phases of clinical trials |
| gptkbp:collaborations |
Research collaborations
|
| gptkbp:community_engagement |
Community outreach programs
|
| gptkbp:competitors |
Key competitors
|
| gptkbp:employees |
Number of employees
|
| gptkbp:financial_performance |
Financial performance metrics
|
| gptkbp:financial_reports |
Annual financial reports
|
| gptkbp:financial_support |
Patient support programs
|
| gptkbp:focus |
Urological diseases
|
| gptkbp:founded |
gptkb:2016
|
| gptkbp:future_plans |
Future growth plans
|
| gptkbp:grants |
Research funding received
|
| gptkbp:head_of_state |
Business development activities
|
| gptkbp:headquarters |
gptkb:New_York_City
|
| https://www.w3.org/2000/01/rdf-schema#label |
Uro Gen Pharma Ltd.
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:instruction_set |
Drug development pipeline
Current product pipeline |
| gptkbp:invention |
Intellectual property strategy
Various patents filed |
| gptkbp:investment |
Investor relations information
Funding rounds Venture capital firms |
| gptkbp:involved_technology |
Technology transfer agreements
|
| gptkbp:key_people |
gptkb:Board_of_Directors
|
| gptkbp:location |
gptkb:United_States
|
| gptkbp:market |
Market research activities
|
| gptkbp:market_launch |
New product launches
|
| gptkbp:market_position |
Global market presence
|
| gptkbp:marketing_strategy |
Market entry strategies
|
| gptkbp:member |
Board member names
|
| gptkbp:mission |
Improve patient outcomes
|
| gptkbp:partnership |
Various pharmaceutical companies
|
| gptkbp:partnerships |
Strategic partnerships
|
| gptkbp:product |
Product development strategies
Uro Gen's product candidates |
| gptkbp:publication |
Scientific publications
|
| gptkbp:regulatory_compliance |
gptkb:Regulatory_compliance_efforts
Regulatory submission history |
| gptkbp:research_areas |
Therapeutic areas of focus
|
| gptkbp:research_focus |
Bladder cancer
Drug delivery systems |
| gptkbp:revenue |
Reported revenue figures
|
| gptkbp:stock_symbol |
URGN
|
| gptkbp:sustainability |
gptkb:Sustainability_initiatives
|
| gptkbp:team |
Leadership team members
|
| gptkbp:technology |
Advanced drug delivery technology
|
| gptkbp:traded_on |
gptkb:NASDAQ
|
| gptkbp:treatment |
Patient clinical outcomes
|
| gptkbp:trends |
Trends in the biotechnology market
|
| gptkbp:type |
gptkb:public_company
|
| gptkbp:vision |
Innovative therapies for urological diseases
|
| gptkbp:website |
www.urogen.com
|
| gptkbp:bfsParent |
gptkb:Uro_Gen
|
| gptkbp:bfsLayer |
6
|